IN8BIO, INC. Operating Expenses
IN8BIO, INC. (INAB) reported Operating Expenses of $4.93 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-06
- IN8BIO, INC. operating expenses for the quarter ending 2026-06-30 was $4.93M, a 5.11% decline year-over-year.
- IN8BIO, INC. operating expenses for the quarter ending 2026-03-31 was $5.27M, a 6.96% decline year-over-year.
- IN8BIO, INC. operating expenses for the quarter ending 2025-12-31 was $5.03M, a 19.14% decline year-over-year.
- IN8BIO, INC. operating expenses for the quarter ending 2025-09-30 was $3.97M, a 44.20% decline year-over-year.
- IN8BIO, INC. operating expenses for fiscal 2025 was $19.86M, a 35.24% decline from fiscal 2024.
- IN8BIO, INC. operating expenses for fiscal 2024 was $30.67M, a 1.09% increase from fiscal 2023.
- IN8BIO, INC. operating expenses for fiscal 2023 was $30.34M, a 6.37% increase from fiscal 2022.
- IN8BIO, INC. operating expenses for fiscal 2022 was $28.52M, a 94.64% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.93M 10-Q · filed 2026-08-06 | $10.20M 10-Q · filed 2026-08-06 | $15.23M derived: sum of 3 quarters · filed 2026-08-06 | $19.20M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $5.27M 10-Q · filed 2026-05-07 | $10.30M derived: sum of 2 quarters · filed 2026-05-07 | $14.27M derived: sum of 3 quarters · filed 2026-05-07 | $19.47M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $5.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $9.00M derived: sum of 2 quarters · filed 2026-03-12 | $14.20M derived: sum of 3 quarters · filed 2026-08-06 | $19.86M 10-K · filed 2026-03-12 |
| 2025-09-30 | $3.97M 10-Q · filed 2025-11-06 | $9.17M derived: sum of 2 quarters · filed 2026-08-06 | $14.83M 10-Q · filed 2025-11-06 | $21.05M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $5.20M 10-Q · filed 2026-08-06 | $10.86M 10-Q · filed 2026-08-06 | $17.09M derived: sum of 3 quarters · filed 2026-08-06 | $24.19M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $5.66M 10-Q · filed 2026-05-07 | $11.88M derived: sum of 2 quarters · filed 2026-05-07 | $18.99M derived: sum of 3 quarters · filed 2026-05-07 | $27.68M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $6.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $13.33M derived: sum of 2 quarters · filed 2026-03-12 | $22.02M derived: sum of 3 quarters · filed 2026-03-12 | $30.67M 10-K · filed 2026-03-12 |
| 2024-09-30 | $7.11M 10-Q · filed 2025-11-06 | $15.80M derived: sum of 2 quarters · filed 2025-11-06 | $24.44M 10-Q · filed 2025-11-06 | $32.04M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $8.69M 10-Q · filed 2025-08-07 | $17.33M 10-Q · filed 2025-08-07 | $24.93M derived: sum of 3 quarters · filed 2025-08-07 | $32.10M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $8.64M 10-Q · filed 2025-05-07 | $16.24M derived: sum of 2 quarters · filed 2025-05-07 | $23.41M derived: sum of 3 quarters · filed 2025-05-07 | $31.13M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | $7.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $14.77M derived: sum of 2 quarters · filed 2025-03-13 | $22.48M derived: sum of 3 quarters · filed 2025-03-13 | $30.34M 10-K · filed 2025-03-13 |
| 2023-09-30 | $7.17M 10-Q · filed 2024-11-12 | $14.88M derived: sum of 2 quarters · filed 2024-11-12 | $22.74M 10-Q · filed 2024-11-12 | $30.54M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $7.71M 10-Q · filed 2024-08-08 | $15.57M 10-Q · filed 2024-08-08 | $23.37M derived: sum of 3 quarters · filed 2024-08-08 | $30.77M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $7.86M 10-Q · filed 2024-05-09 | $15.65M derived: sum of 2 quarters · filed 2024-05-09 | $23.05M derived: sum of 3 quarters · filed 2024-05-09 | $30.23M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $7.80M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $15.20M derived: sum of 2 quarters · filed 2024-03-14 | $22.38M derived: sum of 3 quarters · filed 2024-03-14 | $28.52M 10-K · filed 2024-03-14 |
| 2022-09-30 | $7.40M 10-Q · filed 2023-11-09 | $14.58M derived: sum of 2 quarters · filed 2023-11-09 | $20.72M 10-Q · filed 2023-11-09 | $26.57M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $7.18M 10-Q · filed 2023-08-10 | $13.32M 10-Q · filed 2023-08-10 | $19.17M derived: sum of 3 quarters · filed 2023-08-10 | $22.56M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $6.14M 10-Q · filed 2023-05-12 | $11.99M derived: sum of 2 quarters · filed 2023-05-12 | $15.38M derived: sum of 3 quarters · filed 2023-05-12 | $18.43M derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | $5.85M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $9.24M derived: sum of 2 quarters · filed 2023-03-30 | $12.29M derived: sum of 3 quarters · filed 2023-03-30 | $14.65M 10-K · filed 2023-03-30 |
| 2021-09-30 | $3.39M 10-Q · filed 2022-11-10 | $6.44M derived: sum of 2 quarters · filed 2022-11-10 | $8.80M 10-Q · filed 2022-11-10 | $11.12M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $3.05M 10-Q · filed 2022-08-12 | $5.41M 10-Q · filed 2022-08-12 | $7.72M derived: sum of 3 quarters · filed 2022-08-12 | $9.40M derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | $2.36M 10-Q · filed 2022-05-12 | $4.67M derived: sum of 2 quarters · filed 2022-05-12 | $6.36M derived: sum of 3 quarters · filed 2022-05-12 | $9.23M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $2.31M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $3.99M derived: sum of 2 quarters · filed 2022-03-17 | $6.87M derived: sum of 3 quarters · filed 2022-03-17 | $8.56M 10-K · filed 2022-03-17 |
| 2020-09-30 | $1.68M 10-Q · filed 2021-11-10 | $4.55M derived: sum of 2 quarters · filed 2021-11-10 | $6.25M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $2.87M 10-Q · filed 2021-09-10 | $4.57M 10-Q · filed 2021-09-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| Pluri Inc. (PLUR) | $0.014B | ||
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B |